Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-10-09

FDA Approved: SPRAVATO — Supplemental Application (Janssen Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application for SPRAVATO (esketamine hydrochloride) filed by Janssen Pharmaceuticals Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPRAVATO (ESKETAMINE HYDROCHLORIDE)

Snippet

SUPPL AP for SPRAVATO (ESKETAMINE HYDROCHLORIDE)